You are here

Long-term Prognosis of Antiepilpetic Drug Therapy in People with Newly Diagnosed and Treated Epilepsy

Description 
Antiepileptic drug is the mainstay of treatment modality for epilepsy. People with epilepsy often require lifelong antiepileptic drug treatment. Previous Glasgow study in 2000 demonstrated a-third of the epilepsy patient did not response well to antiepileptic drug therapy. Despite the introduction of more than a dozen new antiepileptic drugs in the past two decades, there remain no robust data to suggest improvement in treatment outcomes in the recent expanded Glasgow study. To valid the prognosis and antiepileptic drug response patterns observed in the Glasgow studies. We will assess treatment outcomes of 796 newly treated epilepsy patients who were seen at a First Seizure Clinic between 1 May 1999 and 31 May 2016 and were prospectively followed for up to 16 years in Australia. We will extract seizure, diagnostic and treatment information from baseline and follow-up clinical documents and construct a digital database. The prognosis and response patterns in the Australia cohort will be compared with the findings in the Glasgow study.
Essential criteria: 
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords 
Antiepilpetic Drug, Newly Diagnosed, Newly Treated, Seizure-free, Epilepsy
School 
Central Clinical School
Available options 
Masters by Research
Honours
BMedSc(Hons)
Time commitment 
Full-time
Physical location 
AMREP
Co-supervisors 
Dr 
Zhibin Chen

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.